232 filings
Page 3 of 12
8-K
x0tu i3pw46j5
23 Mar 21
Other Events
8:21am
8-K
8ms1d 9lceyw
11 Mar 21
Hepion Pharmaceuticals to Present on CRV431 and AI-POWR™ at NASH-TAG 2021
8:38am
8-K
zupuog3fa6
17 Feb 21
Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
8:06am
8-K
nbhzimlj ismw3ee
10 Feb 21
Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference
9:03am
8-K
uu09a7
28 Jan 21
A BETTER APPROACH TO DRUG DEVELOPMENT FOR LIVER DISEASES JANUARY 202 1 | INVESTOR PRESENTATION smart drug smart technology smart development
4:30pm
8-K
zlfbs bhlp0z9c
5 Jan 21
Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences
9:36am
8-K
rppzb6t0p 0twhzal
29 Dec 20
Other Events
4:24pm
8-K
308k2qww
22 Dec 20
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19
8:34am
8-K
f4fyhl2bz
10 Dec 20
Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH
11:32am
8-K
6u75d10q2p rp7jm3fef
2 Dec 20
Other Events
8:12am
8-K
tsl2ikf5ivvll zj5
27 Nov 20
Hepion Pharmaceuticals Prices Public Offering
1:48pm
8-K
t1a4mey37in5hi
20 Nov 20
Termination of a Material Definitive Agreement
4:05pm
8-K
5nf6y
18 Nov 20
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation of Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
8:29am
8-K
21qvgk
17 Nov 20
Hepion Pharmaceuticals to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium
4:53pm
8-K
37be6x6 rn
12 Nov 20
Hepion Pharmaceuticals to Present at The Liver Meeting Digital ExperienceTM 2020
9:33am
8-K
l90dwohalg
10 Nov 20
Hepion Pharmaceuticals Completes First Cohort Enrollment in Phase 2a 'AMBITION' Clinical Trial
10:33am
8-K
odl3f2ra plfwb
27 Oct 20
Other Events
9:45am
8-K
c95qm afip9c
5 Oct 20
Announces Creation of Clinical Pharmacology Analytics Team
9:06am
8-K
owzi2ak
1 Oct 20
Regulation FD Disclosure
4:27pm
8-K
pqbvnahvwbbluq3b
29 Sep 20
Hepion Pharmaceuticals to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference
8:47am